DOX synergy and cardioprotection in breast cancer. I posted it here because I think it's worth staying up on any other potential emerging therapies. This is the first time that I've personally come across something else that enhances anti-cancer efficacy and reduces cardiotoxicity.
From my limited reading CDK7 inhibitors aren't cytotoxic themselves. CDK7i halts cell proliferation and tumor growth, and the killing of the cancer cell would be the job of DOX (augmented by the inhibitor). Bisantrene is cytotoxic, cardioprotective, and synergistic with DOX. Bisantrene still has a leg up here, not to mention all the clinical history.
DOX synergy and cardioprotection in breast cancer. I posted it...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
-0.010(0.81%) |
Mkt cap ! $202.7M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.26 | $1.14 | $381.6K | 320.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7000 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 2171 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.17 |
Change
-0.010 ( 5.54 %) |
||||
| Open | High | Low | Volume | ||
| $1.23 | $1.23 | $1.14 | 48407 | ||
| Last updated 15.52pm 03/05/2024 ? | |||||
| RAC (ASX) Chart |